Pulsed estrogen therapy: pharmacokinetics of intranasal 17-beta-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations
Tóm tắt
Từ khóa
Tài liệu tham khảo
Lievertz R.W. (1987): Pharmacology and pharmacokinetics of estrogens. Am. J. Obstet. Gynecol., 156: 1289–1293.
Judd H.L. (1987): Oestrogen replacement therapy: physiological considerations and new applications. Baillièrse’s Clin. Endocrinol. Metab., 1, 177–206.
Kuhnz W., Gansau C., Mahler M. (1993): Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17β-estradiol. Arzneimittelforschung, 43: 966–973.
Steingold K.A., Laufer L., Chetkowski R.J. et al. (1985): Treatment of hot flushes with transdermal estradiol treatment. J. Clin. Endocrinol. Metab., 61: 627–632.
Selby P.L., McGarricle H.H.G., Peacock M. (1989): Comparison of the effects of oral and transdermal oestradiol administration on oestrogen metabolism, protein synthesis, gonadotrophin release, bone turnover and climacteric symptoms in postmenopausal women. Clin. Endocrinol., 30: 241–249.
McBurney E.I., Noel S.B., Collins J.H. (1989): Contact dermatitis to transdermal estradiol system. J. Am. Acad. Dermatol., 20: 508–510.
Hermens W.A., Belder C.W., Merkus J.M., Hooymans P.M., Verhoef J., Merkus F.W. (1991): Intranasal estradiol administration to oophorectomized women. Eur. J. Obstet. Gynecol. Reprod. Biol., 40: 35–41.
Peron P.G., Cladwell B.V. (Eds) (1970): Immunological methods in steroid determination. New York: Century-Crafts, 87–112.
Toutain P.L. (1995): QL-KINTOOL version 3.1. Pharmacokinetic software. Qualilab, 72, Quai du Châtelet, 45000 Orleans, France.
Yamaoka K., Nakagawa T., Uno T. (1978): Application of Akaike’s Information Criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm., 6: 165–175.
Berner B., John V.A. (1994): Pharmacokinetic characterisation of transdermal delivery systems. Clin. Pharmacokinet., 26: 121–134.
Marty J.P. (1996): New trends in transdermal technologies: development of the skin patch, Menorest®. Int. J. Gynecol. Obstet., 52: S17-S20.
Hankinson S.E., Willett W.C., Manson J.E. et al. (1995): Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J. Natl Cancer Inst., 87: 1297–1302.
Müller P., Botta L., Ezzet F. (1996): Bioavailability of estradiol from a new matrix and a conventional reservoir-type transdermal therapeutic system. Eur. J. Clin. Pharmacol., 51:327–330.
Scott R.T., Ross B., Anderson C., Archer D.F. (1991): Pharmacokinetics of percutaneous estradiol: a crossover study using a gel and a transdermal system in comparison with oral micronized estradiol. Obstet. Gynecol., 77: 758–764.
Marty J-P. (1996): Menorest: technical development and pharmacokinetic profile. Eur. J. Obstet. Gynecol., 64: S29-S33.
Fink B.J., Christensen M.S. (1981): Bioavailability of oestradiol and oestriol administered orally to oophorectomized women. Maturitas, 3: 289–294.
Studd J., Pornel B., Marton I. et al. (1999): Dose-response study of the efficacy and acceptability of intra-nasal 17-β estradiol. Lancet, 353: 1574–1578.
Kuttenn F. (1993): Traitement de la ménopause. Rev. Prat. (Paris), 43: 2593–2595.
Lindsay R., Dempster D.W., Jordan V.C. (Eds) (1997): Estrogens and antiestrogens: basic and clinical aspects. Philadelphia: Lapincott-Raven, 43–62.
Lobo R.A., Cassidenti D.L. (1992): Pharmacokinetics of oral 17β-estradiol. J. Reprod. Med., 37: 77–83.